Intraperitoneal injection but not oral administration of ellagic acid: a novel immunomodulator via targeting casein kinase 2 signaling pathway
Immunosuppressants currently approved for the treatment of autoimmune diseases and organ transplant rejection present diverse adverse effects that impair the life quality of patients. Therefore, the development of novel immunomodulators with high efficiency and low toxicity is essential. Ellagic aci...
Saved in:
| Main Authors: | Wenhui Qi, Bing Han, Tingting Cui, Peixin Shen, Zhuohua Zhao, Yaping Yan, Libin Wang, Xinyu Lu, Yuan Zhang, Xing Li |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tsinghua University Press
2025-07-01
|
| Series: | Food Science and Human Wellness |
| Subjects: | |
| Online Access: | https://www.sciopen.com/article/10.26599/FSHW.2024.9250157 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Long-term safety of azathioprine for treatment of neuromyelitis optica spectrum disorders
by: Ana Beatriz Ayroza Galvão Ribeiro GOMES, et al.
Published: (2021-03-01) -
Therapeutic Potential of Ellagic Acid in Liver Diseases
by: Karolina Wojtunik-Kulesza, et al.
Published: (2025-06-01) -
Postinfectious Aquaporin-4-positive Neuromyelitis Optica Syndrome Disorder and Nephrotic Syndrome
by: Darshankumar Manubhai Raval, et al.
Published: (2025-07-01) -
Neuromyelitis optica spectrum disorder in childhood (a case report)
by: A. S. Kotov, et al.
Published: (2018-01-01) -
Factors for Rituximab Refractoriness in AQP4‐IgG+ NMOSD: A Cohort Study
by: Mariano Marrodan, et al.
Published: (2025-08-01)